Somatic mutations in cytoplasmic IDH1 and mitochondrial IDH2 are common early drivers in glioma and acute myeloid leukaemia (AML) [1], being most frequent in diffuse gliomas and secondary glioblastoma [2]. This evidence concerns the gene IDH2 and acute myeloid leukemia.